Best of ASCO® Vancouver 2024: Merck Breakfast Symposium: Clinical Management of Upper Gastrointestinal (GI) Malignancies in Canada – Dr. Sharlene Gill
OR
Co-Chairs
Dr. Sharlene Gill
Dr. Nancy Nixon
Speakers
Dr. Sharlene Gill
This program has been made possible through unrestricted support from Merck
Studies/trials discussed:
- Clinical management of upper gastrointestinal malingnances in canada
- Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- CheckMate 649 Stysy Design
- KEYNOTE-859 Study Design
- CheckMate 648 Study design
- KEYNOTE-590 Study Design (NCT03189719)
- KEYNOTE-811 Study Design (NCT03615326)
- claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lungand stomach-specific isoforms through alternative splicing
- Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development
- Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
- A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
- Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
- FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
- DESTINY-Gastric 02
- Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
- FIGHT Trial Design
